Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.08, FiscalAI reports.
Unicycive Therapeutics Stock Performance
Shares of UNCY opened at $3.55 on Monday. Unicycive Therapeutics has a 52-week low of $3.33 and a 52-week high of $8.74. The business’s fifty day moving average is $4.19 and its 200-day moving average is $5.94. The firm has a market cap of $98.89 million, a price-to-earnings ratio of -2.03 and a beta of 1.91.
Analyst Upgrades and Downgrades
Several analysts have weighed in on UNCY shares. HC Wainwright dropped their price objective on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, September 4th. Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Finally, Benchmark reiterated a “speculative buy” rating and issued a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.25.
Read Our Latest Analysis on UNCY
About Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Read More
- Five stocks we like better than Unicycive Therapeutics
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
